FDA-approved
Hormones & metabolism
Mecasermin
Evidence
FDA approved
Class
Recombinant IGF-1
KEY TAKEAWAY
Mecasermin is a recombinant version of human insulin-like growth factor 1 (IGF-1), a 70-amino-acid protein. It is sold as Increlex. The FDA approved mecasermin (Increlex) in 2005 for children with severe primary IGF-1 deficiency or certain growth hormone gene deletions.
Written by the Veylo editorial team · Updated
November 2026
What it is
Recombinant IGF-1
Approved for
Severe primary IGF-1 deficiency in children
Key fact
The FDA approved mecasermin (Increlex) in 2005 for children with severe primary IGF-1 deficiency or certain growth hormone gene deletions.
Route
Twice-daily subcutaneous injection
Evidence strength
FDA approved
Mecasermin is a recombinant version of human insulin-like growth factor 1 (IGF-1), a 70-amino-acid protein. It is sold as Increlex.
It replaces IGF-1 in children whose bodies cannot make enough, which allows growth.
The FDA approved mecasermin (Increlex) in 2005 for children with severe primary IGF-1 deficiency or certain growth hormone gene deletions.
Severe primary IGF-1 deficiency in children.
Low blood sugar is the main risk, so it is taken with food. Enlarged tonsils, jaw pain and changes at injection sites are also reported.
U.S. FDA prescribing information for Mecasermin. DailyMed, National Library of Medicine.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.